This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi-Amgen appeal poised to define UPC’s test for inventive step

By Inbar Preiss ( October 23, 2025, 14:12 GMT | Comment) -- In testing a patent's validity, how should "inventive step" be assessed? The UPC’s Court of Appeal is close to providing clarification, following diverging approaches among divisions of the court. Amgen’s appeal against Sanofi was heard earlier this year, and a ruling is expected soon.The pending Unified Patent Court appeal ruling in Sanofi v Amgen could prove decisive in shaping the UPC's long-term approach to inventive step — a test for patent validity that remains unsettled across the court’s divisions....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections